NASDAQ:BPMC

Delisted

Blueprint Medicines Stock News

Healthcare > Biotechnology

Buy BPMC

*Your capital is at risk

$129.46

+0 (+0%)

At Close: Oct 17, 2025

Currently, The Schall Law Firm is Actively Probing Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)

11:00am, Sunday, 09'th Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

Presently, The Schall Law Firm is Conducting Investigations into Potential Securities Law Violations for the Advantage of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)

11:00am, Saturday, 08'th Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

Currently, The Schall Law Firm is Undertaking Probes into Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)

12:45pm, Friday, 07'th Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

At Present, The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC)

11:45am, Thursday, 06'th Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

Currently, The Schall Law Firm Is Probing Allegations For Possible Securities Laws Breaches On Behalf Of Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC)

12:30pm, Wednesday, 05'th Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

The Schall Law Firm is Currently Investigating Claims on Behalf of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC) for Potential Violations of Securities Laws

01:15pm, Tuesday, 04'th Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

02:45pm, Monday, 03'rd Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

11:00am, Sunday, 02'nd Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

IMPORTANT ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

11:00am, Saturday, 01'st Jun 2024

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

IMPORTANT ACTION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

02:30pm, Friday, 31'st May 2024

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

06:01pm, Thursday, 30'th May 2024

-- Breadth of data across 7 presentations, including 4 oral, reflects continued leadership in advancing the understanding and treatment of systemic mastocytosis -- CAMBRIDGE, Mass. , May 30, 2024 /PRN

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

12:15pm, Thursday, 30'th May 2024

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

05:05pm, Thursday, 23'rd May 2024

-- Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities -- -- Earl

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04:01pm, Monday, 06'th May 2024

CAMBRIDGE, Mass. , May 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines' Board of

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

10:51am, Monday, 06'th May 2024

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IM

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by